Clinical studyOfloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections
References (19)
- et al.
Clinical characteristics of culture-positive pneumonia due to Chlamydia pneumoniae
Chlamydia pneumoniae, strain TWAR
Chest
(1989)- et al.
A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections
N Engl J Med
(1986) - et al.
Community- and hospital-acquired pneumonia associated with Chlamydia TWAR infection demonstrated serologically
Arch Intern Med
(1989) - et al.
Countrywide epidemics of Chlamydia pneumoniae, strain TWAR, in Scandinavia, 1981–1983
J Infect Dis
(1989) - et al.
In vitro drug susceptibility of Chlamydia sp strain TWAR
Antimicrob Agents Chemother
(1988) - et al.
Chlamydia species strain TWAR
Infect Control Hosp Epidemiol
(1989) - et al.
Efficacy of ofloxacin as therapy for pneumonia due to Legionella sp, Mycoplasma pneumoniae, Chlamydia psittaci, or Coxiella burnetti
- et al.
Ofloxacin
There are more references available in the full text version of this article.
Cited by (46)
Quinolones
2014, Mandell, Douglas, and Bennett's Principles and Practice of Infectious DiseasesChlamydophila pneumoniae
2010, Infectious Disease Clinics of North AmericaCitation Excerpt :In this study, 1 g of erythromycin per day taken orally for 5 to 10 days was unable to resolve symptoms such that Grayston and colleagues22 later recommended either 2 g of tetracycline per day for 7 to 10 days or 1 g per day for 21 days. In a study by Lipsky and colleagues,58 a clinical response to ofloxacin (400 mg given twice daily for 10 days) was reported in patients with pneumonia and bronchitis caused by C pneumoniae. Infection was defined according to acute- and convalescent-stage sera.
In-vitro activity of moxifloxacin and other fluoroquinolones against Chlamydia species
2002, Journal of Infection and ChemotherapyMicrobiologic efficacy of moxifloxacin for the treatment of community- acquired pneumonia due to Chlamydia pneumoniae
2000, International Journal of Antimicrobial AgentsActivity of grepafloxacin and other fluoroquinones and newer macrolides against recent clinical isolates of Chlamydia pneumoniae
1999, International Journal of Antimicrobial Agents
- 1
Dr. Tack's current address: The Upjohn Company, Kalamazoo, Michigan.
Copyright © 1990 Published by Excerpta Medica Inc.